Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
Glenn J. Hanna(Dana-Farber Cancer Institute), Robert I. Haddad(Georgetown University), Rosh K.V. Sethi(Brigham and Women's Hospital), Kee‐Young Shin(Dana-Farber Cancer Institute), Vickie Y. Jo(Brigham and Women's Hospital), Ann Marie Egloff(Brigham and Women's Hospital), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Jennifer M. Cutler(Dana-Farber Cancer Institute), Laura A. Goguen(Brigham and Women's Hospital), Jason Kass(Brigham and Women's Hospital), Eleni M. Rettig(Dana-Farber Cancer Institute), Donald J. Annino(Harvard University), Kristine Wong(Harvard University), Cloud P. Paweletz(Massachusetts General Hospital), Charles T. Quinn(Dana-Farber Cancer Institute), Michelle Flynn(Dana-Farber Cancer Institute), Ravindra Uppaluri(Brigham and Women's Hospital), Patrick H. Lizotte(Harvard University), Roy B. Tishler(Dana-Farber Cancer Institute), Danielle N. Margalit(Harvard University), Anupam M. Desai(Beth Israel Deaconess Medical Center), Peter C. Everett(Boston Medical Center), Megan E. Cavanaugh(Dana-Farber Cancer Institute), Anne O’Neill(International Breast Cancer Study Group), Jochen H. Lorch(Northwestern University)
Cited by 104
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k